FOLD
NASDAQ
US
Amicus Therapeutics, Inc. - Common Stock
$14.44
▲ +$0.00
(+0.00%)
Vol 3.0M
5
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$4.4B
ROE
-6.8%
Margin
-2.4%
D/E
170.11
Beta
0.41
52W
$6–$14
Wall Street Consensus
14 analysts · Apr 20262
Strong Buy
4
Buy
8
Hold
0
Sell
0
Strong Sell
42.9%
Buy Rating
Price Chart
Similar Stocks
TGTX
TG Therapeutics Inc
P/E 10.6
$4.7B
APLS
Apellis Pharmaceuticals Inc
P/E 70.7
$3.2B
IMVT
Immunovant Inc
$5.1B
APGE
Apogee Therapeutics Inc
$5.2B
DNTH
Dianthus Therapeutics Inc
$1.8B
VKTX
Viking Therapeutics Inc
$4.0B
ACAD
ACADIA Pharmaceuticals Inc
P/E 17.3
$4.5B
SYRE
Spyre Therapeutics Inc
$2.5B
LEGN
Legend Biotech Corp
$4.0B
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.09 | $0.01 | $-0.08 |
| Sep 2025 | $0.04 | $0.06 | +$0.02 |
| Jun 2025 | $-0.12 | $-0.07 | +$0.05 |
| Mar 2025 | $-0.06 | $-0.07 | $-0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $149.7M | $125.2M | $154.7M | $169.1M | $185.2M |
| Net Income | — | $14.7M | -$21.7M | -$24.4M | $17.3M | $1.7M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -19.8% | -19.8% | -19.8% | -19.8% | -6.8% | -6.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -15.8% | -6.7% | -6.7% | -6.7% | -2.4% | -2.4% |
| Gross Margin | 90.2% | 90.4% | 90.4% | 90.4% | 89.8% | 89.8% |
| D/E Ratio | 191.54 | 191.54 | 191.54 | 191.54 | 170.11 | 170.11 |
| Current Ratio | 3.21 | 3.21 | 3.21 | 3.21 | 2.99 | 2.99 |
Key Ratios
ROA (TTM)
-1.7%
P/S (TTM)
7.36
P/B
14.5
EPS (TTM)
$-0.05
CF/Share
$-0.57
Rev Growth 3Y
+20.0%
52W High
$14.36
52W Low
$5.51
$5.51
52-Week Range
$14.36
Financial Health
Free Cash Flow
$16.0M
Net Debt
$228.4M
Cash
$214.0M
Total Debt
$442.4M
As of Dec 31, 2025
How does FOLD compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
FOLD valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
7.4
▼
43%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
14.5
▲
490%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
FOLD profitability vs Biotechnology peers
ROE
-6.8%
▲
90%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-2.4%
▲
99%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
89.8%
▲
14%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-1.7%
▲
96%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
FOLD financial health vs Biotechnology peers
D/E ratio
170.1
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
3.0
▼
33%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.4
▼
58%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
FOLD fundamentals radar
FOLD
Peer median
Industry
FOLD profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
FOLD vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
CAMPBELL BRADLEY LEWIS
Chief Executive Officer · Mar 02
22500 shs
CAMPBELL BRADLEY LEWIS
Chief Executive Officer · Jan 20
75000 shs
CAMPBELL BRADLEY LEWIS
Chief Executive Officer · Jan 20
75000 shs
Last 90 days
Top Holders
Top 5: 33.06%Blackrock Inc.
10.36%
$468.7M
Vanguard Group Inc
9.46%
$428.0M
HBK Investments L P
4.86%
$219.8M
State Street Corporation
4.72%
$213.7M
Pentwater Capital Managemen…
3.66%
$165.7M
As of Dec 31, 2025
Latest News
Samsung Still Leads — But Foldable Rivals Are Closing In Fast
Yahoo Finance · Apr 05
Meta boosts investment in West Texas AI data center by over sixfold …
CNBC · Mar 26
As March Madness unfolds, NY Fed highlights sports betting toll on consumer …
CNBC · Mar 25
Coinbase Global Inc (COIN)’s Stablecoin Revenue Could Grow Sevenfold
Yahoo Finance · Mar 20